Macerich's moves to improve its portfolio quality were necessary
Analysts are decreasing fair value estimate to $29.50 per share from $32.50 per share after incorporating fourth-quarter results and adjusting our assumptions for the impact of the coronavirus.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.